Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial.
Solomon GM, Linnemann RW, Rich R, Streby A, Buehler B, Hunter E, Vijaykumar K, Hunt WR, Brewington JJ, Rab A, Bai SP, Westbrook AL, McNicholas-Bevensee C, Hong J, Manfredi C, Barilla C, Suzuki S, Davis BR, Sorscher EJ.
Solomon GM, et al. Among authors: barilla c.
Lancet Respir Med. 2024 Aug 26:S2213-2600(24)00205-4. doi: 10.1016/S2213-2600(24)00205-4. Online ahead of print.
Lancet Respir Med. 2024.
PMID: 39208836